Nucleoside and nucleotide analogs are used as antiviral agents for several infections such as different types of viral hepatitis, human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) and herpes virus infections.
On May 6, 2021, a study published in the top journal New England Journal of Medicine (NEJM) brings important evidence for this. A research team led by scholars from the University of Copenhagen tested four different strategies and found the most beneficial way to maintain long-term weight loss and improve overall health: a combination of weight-loss drugs and lifestyle changes, rather than relying on a single approach.
In a study published in Nature Communications on May 14, a research team led by scientists from University College London (UCL) found a new target for the treatment of hepatitis B. The targeted therapy of HBV can not only inhibit the replication of HBV, but also stimulate T cell activity against HBV-infected liver cells. The researchers said that this target may bring a highly effective and innovative therapy for the treatment of chronic HBV infection and liver cancer.
Prostate cancer is cancer that occurs in the prostate. It is the most common cancer among men (after skin cancer). Unfortunately, metastatic castration-resistant prostate cancer (mCRPC) is still incurable.
Recently, Hunan Huateng Pharmaceutical Co., Ltd.(hereafter called Huateng Pharma) completed a series B financing of 117 million yuan. This round of financing was led by CITIC Securities, followed by Hunan Xingxiang Group, Shenzhen Hongfu No. 7, and Zhou Qilin, an academician of the Chinese Academy of Sciences.
Huateng Pharmac raised 50 million yuan in the series A round of funding led by Tianshili Capital's Boyi Fund and followed by Zhuhai Danchi Equity Investment Fund, and Hunan Dingteng Juzhi Investment Partnership.